Virpax Pharmaceuticals, Inc.
DelistedCIK 1708331fmd_1ZVHQ755DX3Q6ASE7Q668MVW6FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2024, 20 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Research and development | 1 | 5 | 11 | 5 | 6 |
| Total operating expenses | 4 | 12 | 22 | 16 | 12 |
| Operating income | (4) | (12) | (22) | (16) | (12) |
| Interest expense | 0 | 0 | – | – | 0 |
| Other non-operating income (expense) | (0) | (0) | 0 | 1 | 0 |
| Income before taxes | (4) | (12) | (22) | (15) | – |
| Net income | (4) | (12) | (22) | (15) | (12) |
| Net income to common shareholders | – | – | – | 15 | 12 |